Stock Market Today: Dow Jones, S&P 500 Futures Slip After Weaker-Than-Expected GDP Report—Grail, Candel Therapeutics, Copart In Focus (UPDATED)

U.S. stock futures rose on Friday ahead of Q4 GDP data and PCE inflation gauge releases. Markets are pricing in a 94% likelihood of unchanged Fed rates in March. Notable movers include Copart missing earnings expectations, Comfort Systems raising dividends, Grail plunging 47% on weak earnings, Candel Therapeutics declining on stock offering announcement, and Dropbox falling despite beating earnings. Wells Fargo strategist recommends leaning into growth-sensitive sectors like Financials and Industrials rather than defensive positioning.

02/20/2026, 8:56 AM • Benzinga

Stock Market Today: Dow Jones, S&P 500 Futures Rise Ahead Of Q4 GDP Numbers—Grail, Candel Therapeutics, Copart In Focus

U.S. stock futures rose on Friday ahead of Q4 GDP data and PCE inflation gauge releases. Markets are pricing in a 94% likelihood of unchanged Fed rates in March. Notable movers include Copart missing earnings expectations, Comfort Systems raising dividends, Grail plunging 47% on weak earnings, Candel Therapeutics declining on stock offering announcement, and Dropbox falling despite beating earnings. Wells Fargo strategist recommends leaning into growth-sensitive sectors like Financials and Industrials rather than defensive positioning.

02/20/2026, 4:57 AM • Benzinga

Candel Therapeutics Announces Pricing of Public Offering

Candel Therapeutics announced a public offering of 18.3 million shares at $5.45 per share, raising $100 million in gross proceeds. The company plans to use the funds for launch readiness and commercialization of aglatimagene besadenovec for localized prostate cancer, ongoing phase 3 trials in non-small cell lung cancer, and general corporate purposes. The offering is expected to close on February 23, 2026.

02/19/2026, 9:40 PM • GlobeNewswire

Candel Therapeutics Announces Proposed $100 Million Public Offering

Candel Therapeutics (NASDAQ: CADL) announced a proposed $100 million public offering of common stock, with an additional $15 million option for underwriters. The company plans to use proceeds for launch readiness, commercialization activities, and development of aglatimagene for prostate cancer and non-small cell lung cancer, along with general corporate purposes. Citigroup, Cantor, and Stifel are acting as joint bookrunning managers.

02/19/2026, 4:05 PM • Benzinga

Oncolytic Virotherapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The global oncolytic virotherapy market is projected to grow from USD 49.73 million in 2025 to USD 153.31 million by 2031, with a CAGR of 20.64%. Growth is driven by rising cancer incidence, advances in genetic engineering, and synergistic combination therapies with checkpoint inhibitors. However, host immune system challenges and premature viral clearance remain significant obstacles to market expansion.

01/23/2026, 5:52 AM • GlobeNewswire

Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors

Candel Therapeutics presented three key research presentations at SITC 2025, highlighting advances in immunotherapy for solid tumors using multi-omics analysis and artificial intelligence, including promising phase 3 clinical trial results for CAN-2409 in prostate cancer and preclinical data from their enLIGHTEN™ Discovery Platform.

11/04/2025, 9:00 AM • GlobeNewswire